Psychedelics stocks

Definium directly owns DT120, a lysergide ODT in Phase 3 development for MDD and other psychiatric indications.

Definium is the direct beneficiary of the FDA Breakthrough Therapy designation and positive Phase 3 MDD results for DT120. The designation can accelerate FDA interaction and review, while the reported 8.1-point placebo-adjusted MADRS improvement strengthens DT120's regulatory, partnering, financing, and eventual commercial prospects. DT120 remains investigational, so approval and commercialization risks remain.

ATAI's core business is focused entirely on these therapeutic areas, primarily BPL-003 and VLS-01 for TRD.

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Compass is developing psilocybin specifically for TRD in Phase 3 trials.

Compass is developing COMP360, an investigational psilocybin therapy for treatment-resistant depression. Although its modality differs from the NRX-101/TMS combination, successful SPARC-TMS results could intensify competition for TRD patients, clinical infrastructure, psychiatric prescriber attention, and specialist capital.

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.

Psyence has an identified U.S. cGMP manufacturing pathway for pharmaceutical-grade ibogaine API and an associated supply and distribution arrangement, making it the clearest listed-company beneficiary of Schedule I clinical-supply expansion.

Psyence BioMed is directly positioned to benefit from the newly advancing U.S. ibogaine research pathway. Its Texas subsidiary entered a manufacturing partnership for pharmaceutical-grade ibogaine API under cGMP standards, and the company states that compliant U.S. production could support future research and clinical-development programs. The FDA-funded trials therefore increase the probability of demand for Psyence’s ibogaine supply and development platform, although no federal contract or approval is confirmed.

Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.

Based in Princeton, Canada, Optimi Health Corp., established in 2020, is a Canadian entity focused on manufacturing pharmaceutical and nutraceutical products. The company produces and supplies controlled substances, including finalized MDMA and psilocybin drug products, directly to authorized clinics, pharmacies, research trials, and collaborative partners. Their diverse product portfolio extends to MDMA, natural psilocybin, psilocin, other psychedelic compounds, and functional mushrooms, all derived from botanical sources and aimed at the health and wellness market. Optimi Health's operations span cultivation, processing, and distribution of raw mushroom biomass, alongside the creation of mushroom extracts, pharmaceutical drug products, and dietary supplements. These items are available for purchase through the Amazon marketplace, via distributors and brokers, and directly online.

Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily engaged in creating modified botanical Schedule 1 molecules for use within the United States. The firm's pipeline encompasses five entirely synthetic, proprietary prodrugs that are currently in preclinical development, each designed to tackle a unique set of medical conditions. Specifically, these include a psychedelic compound derived from mushrooms, aimed at treating post-traumatic stress disorder and depression; an innovative cannabinoid and tree bark-sourced psychedelic intended to combat addiction; and three additional cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and inflammation of the eye. Established in 2014 and headquartered in New York, New York, the company was previously named Gridiron BioNutrients, Inc. before adopting its current moniker, Innovation1 Biotech Inc., in March 2022.

Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

MYND Life Sciences Inc. operates as a neuro-pharmaceutical company, applying life science principles to develop innovative treatments for depressive conditions. The firm conducts scientific research and clinical trials in Canada and the United States, concentrating on therapeutic compounds that possess neuro-anti-inflammatory properties. A significant part of its research involves the in-depth study of psilocin and psilocybin extracts, along with their various analogs. The company's principal office is situated in Kelowna, Canada.

BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-based technologies, designed to engage the immune system in combating viral infections. Its active development pipeline includes BETR-001, intended for major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another key asset, BETR-002, is being advanced to address benzodiazepine dependency, anxiety, and spasticity. Further in development are MM-003 for COVID-19 and other respiratory viral infections; MM-001, a topical intravaginal cream for HPV-induced cervical intraepithelial neoplasia; and AP-002, designated for cancer treatment. BetterLife Pharma Inc. maintains a research collaboration with the University of California San Diego, focusing on preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. Headquartered in Vancouver, Canada, the company was founded in 2002 and was formerly known as Pivot Pharmaceuticals Inc. before adopting the name BetterLife Pharma Inc. in December 2019.

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

Revitalist Lifestyle and Wellness Ltd. (RVLWF) is a healthcare provider that operates medical clinics, specializing in a range of innovative mental health treatments. Its offerings include advanced therapeutic approaches like ketamine-enhanced and psychedelic-enhanced psychotherapy, along with medicative infusion therapy, vitamin infusions, and transcranial magnetic stimulation (TMS). The company also provides traditional psychotherapy, other pharmacological interventions, and acupuncture. Founded in 2018, Revitalist has its corporate headquarters in Vancouver, Canada. As of March 31, 2022, it maintained a network of nine clinics located throughout the United States.

Braxia Scientific Corp. functions as a medical research entity that also runs clinics, offering ketamine therapies to individuals suffering from depression and linked conditions. Beyond its clinical services, the company is actively engaged in discovering and bringing to market novel pharmaceutical compounds and innovative delivery methods. Leveraging its intellectual property development platform, Braxia Scientific innovates by developing derivatives of ketamine and psilocybin, in addition to other psychedelic substances. The organization further owns and operates several multidisciplinary clinics focused on treating a broad spectrum of mental health disorders. Braxia Scientific Corp.'s main office is located in Mississauga, Ontario.

Delic Holdings Corp. (DELCF) provides a range of medical services and treatments across the United States and Canada. The company manages several key initiatives, including "The Delic," an innovative creative platform designed to facilitate public discussions about psychedelic culture. It also orchestrates "Meet Delic" events, which delve into vital subjects such as safety protocols, harm reduction, the interplay of psychedelics with mental health and the entertainment industry, personal integration, human performance enhancement, and various medical applications. Furthermore, Delic operates "Reality Sandwich," a comprehensive online educational hub offering approximately 10,000 pieces of content, encompassing psychedelic guides, current news, and cultural insights. Its "Delic Radio" podcast features expert-led conversations on topics spanning psychedelic news, scientific research, cultural implications, therapeutic uses, current affairs, and policy. Beyond its media platforms, Delic Holdings is actively engaged in developing intellectual property through dedicated research and development efforts in both the cannabis and psychedelic sectors. The company also owns and operates a total of fifteen ketamine infusion treatment clinics. Delic Holdings Corp. maintains its headquarters in Vancouver, Canada.

With its origins as KetamineOne Capital Limited, this innovative wellness organization is dedicated to advancing ketamine-assisted therapy and psychedelic medicines. It achieves this mission by managing a network of healthcare clinics across North America. The company, which commenced operations in 2017 and is headquartered in Vancouver, Canada, was formerly recognized as Myconic Capital Corp. Its transition to the KetamineOne Capital Limited name occurred in June 2021.

TripSitter Clinic Ltd., headquartered in Toronto, Canada, provides a digital healthcare platform operating as a virtual clinic. This service links patients across the United States with qualified physicians who assess their eligibility for a prescribed treatment program utilizing low-dose oral ketamine medication. The platform is designed to assist individuals suffering from a variety of mental health conditions, such as depression, anxiety, post-traumatic stress disorder, bipolar disorder, and obsessive-compulsive disorder. Their comprehensive subscription plan includes initial physician consultations, the provision of oral ketamine prescriptions, facilitated treatment sessions with a licensed medical practitioner, and direct messaging access to that professional. Currently, the company extends its services to clients located in California, Illinois, Arizona, Colorado, Michigan, Washington, Florida, New York, Ohio, and Virginia.

Pharmadrug Inc., a Toronto-based specialty pharmaceutical firm, is dedicated to the research, development, and market introduction of controlled substances and natural therapeutics, such as psychedelics, cannabis, and other approved compounds derived from nature. The company also manages the import and supply of medical cannabis to pharmacies across Germany and the broader European Union. Additionally, it operates Super Smart, an entity focused on advancing the application of functional and psilocybin mushrooms, and engages in studies to reformulate established natural medicines. Pharmadrug maintains key research collaborations, including an agreement with the University of Michigan to explore the potential role of N, N-dimethyltryptamine (DMT) in various states of consciousness. It has also partnered with the Southwest Research Institute for the manufacturing of cepharanthine and entered into a clinical trial agreement with Johns Hopkins University to compare the acute and enduring psychological and neural effects of DMT against another potent active molecule. The company adopted its current name in October 2019, having previously operated as Aura Health Inc.

Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.

Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.

Noveris Health Sciences Inc. operates as a biotechnology firm dedicated to the investigation, pharmaceutical development, and clinical evaluation of psilocybin-based products. Co-founded by Parente Carman, Damon Michaels, and Robert Roscow on September 27, 2013, the company maintains its headquarters in Vancouver, Canada.

Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.

Wesana Health Holdings Inc. is a life sciences firm dedicated to advancing and providing psychedelic-based therapies, including psilocybin-enhanced psychotherapy, primarily targeting the treatment of traumatic brain injuries (TBI). The company focuses on pioneering scientifically validated compounds and therapeutic strategies. Its mission is to enable patients suffering from trauma-related neurological, psychological, and mental health conditions to achieve recovery. Wesana Health is headquartered in Chicago, Illinois.

PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company was founded on October 28, 2009 and is headquartered in Sunrise, FL.

Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.